Merck & Co., Inc. (MRK) Stock: Price, Forecast & Analyst Target
Merck & Co., Inc. (MRK) — MoonshotScore 69/100 (Strong band), calculated Nov 18, 2026. Price $137.78 (-3.90%), as of the Nov 18, 2026 trading session; market cap $340B. Expected results Feb 2, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Merck & Co., Inc. · MRK · NYSE · Healthcare · Drug Manufacturers - General
Research dated 2026-09-12: Merck sells human medicines and vaccines through pharmaceutical channels, while its animal-health arm supplies veterinary drugs, vaccines and digital identification and monitoring tools. The decisive issue is whether cash-generative operations can absorb the recent surge in research expense and restore reported profitability without revenue losing momentum.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Merck & Co. (MRK)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but a strained balance sheet and a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Strained; Valuation: Full; Growth Durability: Flat; Momentum: Surging.
- EPS beat 0 of the last 4 reports
- expected results Feb 2, 2027
- Altman Z 3.87 · Piotroski F 5
Holding back: balance-sheet strain
Helping: business quality, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 75 | Strong | |
| 73 | Strong | |
| 72 | Strong | |
| 72 | Strong | |
| 69 | Strong | |
| 69 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $137.78 | |
| Change on the day | -3.90% | |
| 52-week range | $92.11–$156.92 | |
| Market capitalisation | $340B | — |
| Price / earnings (trailing) | 144.82 | |
| Shares traded on the day | 9.69M | |
| Beta (volatility vs the S&P 500) | 0.22 |
Why Merck & Co. scores 69
Share price, last 12 months +71.4%
$86.75 $148.71
What the price assumes
10.1% a year of free-cash-flow growth for ten years is what a $366.89B market value ( snapshot) asks for.
The growth the price implies sits inside what the business has recently delivered, so the valuation leans on that record continuing. It also runs ahead of the analysts' revenue path.
Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $14.75B. Inputs: FMP statements, estimates and quote.
How the stock reacts to earnings
EPS beat in 11 of the last 12 reports (2024–2026); the stock still fell the next session after 4 of those beats. Average first-session move: 4.4% either way.
- +4.7%Feb ’24
- +3.3%Apr ’24
- -11.5%Jul ’24
- -2.8%Oct ’24
- -10.1%Feb ’25
- +5.1%Apr ’25
- -2.7%Jul ’25
- -0.7%Oct ’25
- +4.4%Feb ’26
- +1.1%Apr ’26
- +0.4%Aug ’26
- +6.1%Oct ’26
Every report, with revenue and five-session moves
| Report | EPS | Revenue | Next session | 5 sessions |
|---|---|---|---|---|
| Beat | Beat | +6.1% | +4.3% | |
| Beat | Beat | +0.4% | +2.1% | |
| Beat | Beat | +1.1% | +1.2% | |
| Beat | Beat | +4.4% | +3.3% | |
| Beat | Beat | -0.7% | -0.9% | |
| Beat | In line | -2.7% | -3.9% | |
| Beat | Beat | +5.1% | +5.8% | |
| Miss | In line | -10.1% | -13.3% | |
| Beat | Beat | -2.8% | -3.5% | |
| Beat | Beat | -11.5% | -13.0% | |
| Beat | Beat | +3.3% | +1.0% | |
| Beat | In line | +4.7% | +4.8% |
Beats have usually been rewarded — 7 of 11 drew a higher close the next session.
What management is saying differently
Management's own words on the Q3 FY2026 call () against Q2 FY2026 (). Analysts' questions are left out.
- New this call: “sac tmt”, “keytruda loe”, “heart failure”, “term growth” — none of them came up in Q2 FY2026.
- Getting louder: “long term” (1 → 9 mentions), “lung cancer” (2 → 9 mentions), “cell lung” (2 → 8 mentions).
- Gone quiet: “forward-looking statements”, “investor event”, “oral once-weekly”, “rheumatoid arthritis” — regular themes last call, absent this time.
- Tone: Cautious words such as “may”, “could” and “headwind” fell from 3.9 to 2.7 per 1,000 words, and confident words such as “record” and “strong” rose from 4.4 to 5.5.
Management sounded more assured than a quarter earlier — fewer hedging words, more of the confident kind.
Our track record on this stock
Since the score went from 74 to 69 while the share price moved -8.5% through .
The score has stayed in the Strong band across the stretch we have recorded; we grade each band change three months after it happens.
The crowd against our signals
- Analysts: 68% of 38 rate it a buy; the average target sits +16.5% from the price of $137.78.
- Last 90 days: 2 upgrades and 1 downgrade among 24 rating actions.
- Our signals: Strong band; strongest pillar Momentum (89), weakest Financial Safety (29).
Here we and the crowd agree.
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Merck & Co. (MRK): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company less favourably than the MoonshotScore does: Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Merck & Co. (MRK), and what does it report?
Short answer · as of
Merck commercializes therapies across oncology, hospital care, immunology, neuroscience, virology, cardiovascular disease and diabetes, alongside preventive vaccines.
Research dated 2026-09-12.
Demand reaches Merck through wholesalers, pharmacies, hospitals, government agencies, managed-care organizations, physicians and other institutional customers.
Pharmaceuticals provide the overwhelming share of reported sales. Animal Health is smaller but economically distinct, tying Merck to veterinary care, livestock production and animal monitoring rather than making the company solely dependent on human medicines.
What do the latest results show for Merck & Co. (MRK)?
Research dated 2026-09-12.
Revenue remained near its elevated base and improved in the latest reported period, while gross profit eased and operating and net results stayed negative. Losses narrowed from the preceding period, but research expense remained far above its earlier quarterly run rate; unusually heavy research spending, rather than collapsing sales, is the defining feature of the recent accounts.
The earnings-history measure was less negative than expected, while revenue also cleared the estimate. Management separately attributed its elevated full-year tax expectation to the nondeductible onetime Terns charge; that comment explains the tax outlook, not the research-spending surge.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $17.28B | $5.79B | $2.32 (diluted) |
| Q4 FY2025 | $16.40B | $2.96B | $1.19 (diluted) |
| Q1 FY2026 | $16.29B | -$4.24B | -$1.72 (diluted) |
| Q2 FY2026 | $16.61B | -$1.33B | -$0.54 (diluted) |
What are the financial strengths and risks for Merck & Co. (MRK)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Operating cash flow remained positive throughout the displayed series and strengthened in the latest period, comfortably covering capital expenditure even while accounting results showed losses. Short-term liquidity ratios sit above parity, but total debt greatly exceeds liquid holdings, making Merck cash-generative rather than net-cash funded.
Cash and short-term investments have declined across the reported window despite a recent rebound. Pharmaceutical concentration compounds that balance-sheet pressure: failure of the human medicines and vaccines portfolio to offset heavy research expense would squeeze earnings and reduce room to rebuild liquidity while carrying the debt load.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Rich valuation — a P/E of 144.82 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
What should you watch next at Merck & Co. (MRK)?
Short answer · as of
The next earnings report is expected on Feb 2, 2027.
Research dated 2026-09-12.
The next report should be read for a return to operating and net profitability, movement in research expense, and whether revenue extends its latest improvement. Cash conversion deserves equal attention because operating cash strengthened while reported earnings remained negative.
Watch whether liquid balances continue recovering and whether management preserves its announced product-launch timetable. Longer-range estimates anticipate revenue expansion before becoming comparatively flatter, so the useful test is execution against that path rather than the consensus label itself.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Merck & Co. compare with its peers?
Short answer
Merck & Co.'s score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Compared with a pure human-pharmaceutical manufacturer, Merck contains a commercially meaningful animal-health franchise. That operation sells veterinary medicines and vaccines to veterinarians and livestock producers, then extends the relationship through identification, traceability and continuous-monitoring products.
Pharmaceuticals still dwarf Animal Health in reported sales. The animal franchise diversifies customers and demand channels, but Merck’s consolidated economics remain dominated by commercialization and research in human health.
| Company | Price | Market value | Score |
|---|---|---|---|
| $1382.75 Nov 18, 2026 | $1.23T | 98 5-pillar Nov 18, 2026 | |
| $39.43 Nov 18, 2026 | $174B | 87 5-pillar Nov 18, 2026 | |
| $47.12 Nov 18, 2026 | $113B | 87 5-pillar Nov 18, 2026 | |
| $178.76 Nov 18, 2026 | $277B | 85 5-pillar Nov 18, 2026 | |
| $59.56 Nov 18, 2026 | $122B | 85 5-pillar Nov 18, 2026 | |
| $443.89 Nov 18, 2026 | $240B | 84 5-pillar Nov 18, 2026 | |
| $286.01 Nov 18, 2026 | $506B | 83 5-pillar Nov 18, 2026 | |
| $272.70 Nov 18, 2026 | $656B | 83 5-pillar Nov 18, 2026 | |
| $155.21 Nov 18, 2026 | $293B | 82 5-pillar Nov 18, 2026 | |
| $48.58 Nov 18, 2026 | $97.4B | 77 5-pillar Nov 18, 2026 | |
| $168.98 Nov 18, 2026 | $210B | 72 5-pillar Nov 18, 2026 | |
| $692.74 Nov 18, 2026 | $257B | 70 5-pillar Nov 18, 2026 | |
| Merck & Co. (MRK) — this page | $137.78 | $340B | 69 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $105.00 – $180.00
- Consensus target
- $159.45
- Median target
- $165.00
Consensus record · Captured .
Measured against a quoted price of $137.78 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 12, 2026
- Transactions
- 51
- Identified insiders
- 18
- Purchases
- 0
- Sales
- 14
- Other transactions
- 37
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held MRK in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported MRK in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Merck & Co. (MRK)?
MRK Healthcare Stock FAQ
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How important is Merck Animal Health beside its pharmaceutical business?
Animal Health is a substantial standalone operation, but pharmaceuticals contribute the overwhelming majority of segment revenue. Its value is diversification into veterinary and livestock demand, not equal balance with human health.
Why did Merck post losses while revenue stayed resilient?
The losses coincided with research expense rising far above its earlier quarterly pattern. Revenue remained resilient and the latest loss narrowed, so the recent deterioration is concentrated in reported costs rather than a broad sales collapse.
What does Merck sell to veterinarians and livestock producers?
Merck supplies veterinary medicines and vaccines, along with tools for animal identification, traceability and continuous monitoring. This creates a demand stream linked to animal care and livestock management rather than human prescribing.
How does the Terns charge affect Merck’s outlook?
Management says the nondeductible onetime Terns charge raises the expected full-year tax rate. It explains the tax guidance but should not be treated as an explanation for the operating loss or research-spending surge.
What is the MRK stock price today?
The last price recorded for Merck & Co., Inc. (MRK), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the MRK price target?
The analyst consensus price target for Merck & Co., Inc. (MRK), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Reviewed by Sedat ANAK, Founder and Editor-in-Chief, on 2026-11-07.
Sources: the source register lists the 24 figures on this page — 1 from SEC filings and earnings calls, 19 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold MRK
Funds in our ETF coverage that list MRK among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
